Enveric Biosciences, Inc.
ENVB
$6.11
$0.071.16%
NASDAQ
| 06/30/2025 | 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | |
|---|---|---|---|---|---|
| Net Income | -15.30% | 30.74% | -51.37% | -10.89% | 23.51% |
| Total Depreciation and Amortization | -50.62% | -1.82% | -2.71% | 0.00% | -0.70% |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | 7.84% | -78.34% | 138.60% | 5.47% | 6.33% |
| Change in Net Operating Assets | 179.93% | -154.59% | 24.99% | 148.55% | -159.58% |
| Cash from Operations | 20.97% | -82.36% | -41.46% | 67.91% | -11.20% |
| Capital Expenditure | -- | -- | -- | -- | -- |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | -- | -- | -- | -- | -- |
| Cash from Investing | -- | -- | -- | -- | -- |
| Total Debt Issued | -- | -- | -- | -- | -- |
| Total Debt Repaid | -- | -- | -- | -- | -- |
| Issuance of Common Stock | -89.91% | 819.57% | -6.57% | 702.79% | -98.71% |
| Repurchase of Common Stock | -- | -- | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -- | -- | -20,300.00% | 99.67% | -101.80% |
| Cash from Financing | -89.91% | 860.06% | -10.49% | 1,404.94% | -99.48% |
| Foreign Exchange rate Adjustments | 7.69% | 82.74% | -222.16% | 1,323.08% | -83.95% |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | -170.35% | 335.83% | -122.74% | 86.30% | -170.14% |